Preliminary Evaluation of the Safety and Tolerability of SPOT-mRNA01 Subcutaneously Administered in Healthy Subjects
Launched by SPOT BIOSYSTEMS LTD. · May 30, 2024
Trial Information
Current as of February 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
SPOT-mRNA01 (collagen 1 alpha 1 (COL1A1) mRNA-loaded EVs) can induce collagen protein grafts in dermal tissue, thereby supplementing collagen and reducing wrinkle formation in collagen-depleted skin. Therefore, SPOT-mRNA01 can provide a source of human collagen intradermally for cosmetic anti-aging use.
This is a first-in-human randomized, double-blind, placebo-controlled, single-dose, dose ascending, exploratory clinical study to evaluate the Safety and Tolerability of SPOT-mRNA01 administered by subcutaneous injection to healthy adult volunteers.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Aged 18 to 75 years inclusive at the time of informed consent.
- Exclusion Criteria:
- • 1. Any transient or chronic skin condition, disorder, or infection within 20 cm of the target areas before treatment that, in the opinion of the investigator, may confound study results.
- • 2. History of laser treatment or chemical peels or any cosmetic anti-aging treatments to the target areas within six months of the study treatment.
- • 3. History of surgical procedures to target areas, including removal of benign or malignant skin cancers that, in the opinion of the investigator, may confound study results.
- • 4. Participant with a history of heavy smoking, alcohol or drug abuse or steroid treatment.
- • 5. Pregnant or breast-feeding females.
- • 6. History of anaphylaxis or allergic reactions to any constituent of the study product and/or local anesthetics, and/or history of severe abnormal drug reaction.
- • 7. Those who have participated in clinical trials of other investigational drugs within 3 months before the study treatment.
- • 8. Those who are not suitable for subcutaneous injection and biopsy.
- • 9. Any condition that the investigator or primary physician believes may not be appropriate for participating the study.
- • -
About Spot Biosystems Ltd.
Spot Biosystems Ltd. is an innovative biotechnology company dedicated to advancing healthcare through the development of cutting-edge diagnostic solutions. Focused on harnessing the power of biosensors and advanced analytics, Spot Biosystems aims to enhance patient outcomes by providing rapid, accurate, and user-friendly diagnostic tools. With a commitment to research and development, the company collaborates with leading researchers and institutions to drive the translation of scientific discoveries into practical applications, ultimately improving disease detection and management. Leveraging a multidisciplinary approach, Spot Biosystems is poised to make significant contributions to the fields of diagnostics and precision medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0